Tenofovir (all routes except local)

Child/Infant death (> 28 days of life)

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S5265
R13637		 Mugo, 2014 Infant death (< 1 year) early pregnancy randomized controlled trial unexposed, sick Adjustment: Randomisation Control group: Unexposed, sick Exposed group: TDF (only) Indication: PrEP 0.19 [0.02;1.78] C 1/81   4/66 5 81
ref
S5122
R13280		 Gibb, 2012 Post-natal mortality (at 6- and 12-months) throughout pregnancy prospective cohort exposed to other treatment, sick Adjustment: No Control group: zidovudine/lamivudine-based Exposed group: TDF/zidovudine/lamivudine Indication: HIV 0.63 [0.20;1.96] C 7/111   6/62 13 111
ref
Total 2 studies 0.49 [0.18;1.35] 18 192
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Mugo, 2014Mugo, 2014 0.19[0.02; 1.78]58121%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Gibb, 2012Gibb, 2012 0.63[0.20; 1.96]1311179%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Total (2 studies) I2 = 0% 0.49[0.18; 1.35]181920.02.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 0.63[0.20; 1.96]13111 -NAGibb, 2012 1 case control studiescase control studies 0 RCTRCT 0.19[0.02; 1.78]581 -NAMugo, 2014 1 Type of controls unexposed, sickunexposed, sick 0.19[0.02; 1.78]581 -NAMugo, 2014 1 exposed to other treatment, sickexposed to other treatment, sick 0.63[0.20; 1.96]13111 -NAGibb, 2012 1 Tags Adjustment   - No  - No 0.63[0.20; 1.96]13111 -NAGibb, 2012 1   - Randomisation  - Randomisation 0.19[0.02; 1.78]581 -NAMugo, 2014 1 Control group   - Unexposed, sick  - Unexposed, sick 0.19[0.02; 1.78]581 -NAMugo, 2014 1   - zidovudine/lamivudine-based  - zidovudine/lamivudine-based 0.63[0.20; 1.96]13111 -NAGibb, 2012 1 Exposed group   - TDF (only)  - TDF (only) 0.19[0.02; 1.78]581 -NAMugo, 2014 1   - TDF/zidovudine/lamivudine  - TDF/zidovudine/lamivudine 0.63[0.20; 1.96]13111 -NAGibb, 2012 1 Indication   - HIV  - HIV 0.63[0.20; 1.96]13111 -NAGibb, 2012 1   - PrEP  - PrEP 0.19[0.02; 1.78]581 -NAMugo, 2014 1 All studiesAll studies 0.49[0.18; 1.35]181920%NAMugo, 2014 Gibb, 2012 20.010.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed, sick controlsunexposed, sick controls Out of scale0.19[0.02; 1.78]581 -NAMugo, 2014 1 exposed to other treatment, sick controlsexposed to other treatment, sick controls 0.63[0.20; 1.96]13111 -NAGibb, 2012 10.510.01.0